LANXESS (DE:LXS)
XETRA:LXS
Want to see DE:LXS full AI Analyst Report?
Top Page
LANXESS
(XETRA:LXS)
Select Model
Select Model
Rating:49Neutral
Price Target:
€17.50
▼(-2.13% Downside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak financial performance (declining revenue and persistent losses with volatile cash generation). Offsetting factors include a broadly neutral technical setup and a cautiously constructive earnings-call outlook (maintained guidance and expected Q2 improvement), while valuation signals are mixed due to losses despite a relatively high dividend yield.
Positive Factors
Diversified specialty-chemicals portfolio
LANXESS sells a broad mix of specialty chemicals and water-treatment products into automotive, construction, electronics, agro and industrial customers. This product and end-market diversification supports more stable long-term demand, reduces single-market cyclicality, and enables customer-specific formulations that foster stickier revenue streams.
Negative Factors
Declining revenues and persistent losses
Revenues have trended down multi-year and the company reported operating and net losses across recent years. Persistent top-line weakness combined with recurring losses undermines sustainable profitability, limits retained-earnings rebuild, and constrains capacity to self-fund strategic initiatives without improved structural demand or margin recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified specialty-chemicals portfolio
LANXESS sells a broad mix of specialty chemicals and water-treatment products into automotive, construction, electronics, agro and industrial customers. This product and end-market diversification supports more stable long-term demand, reduces single-market cyclicality, and enables customer-specific formulations that foster stickier revenue streams.
Read all positive factors
LANXESS (LXS) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.60B
Dividend Yield0.59%
Average Volume (3M)709.84K
Price to Earnings (P/E)―
Beta (1Y)1.88
Revenue Growth-14.31%
EPS Growth-386.04%
CountryDE
Employees12,320
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-7.65
Shares Outstanding86,346,306
10 Day Avg. Volume711,662
30 Day Avg. Volume709,842
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.27
P/FCF Ratio-27.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.40Price Target Upside-2.68% Downside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)0.03
Revenue Forecast (FY)€5.85B
LANXESS Business Overview & Revenue Model
Company Description
LANXESS Aktiengesellschaft, a specialty chemicals company, develops, manufactures, and markets chemical intermediates, additives, specialty chemicals, and plastics worldwide. It operates through four segments: Advanced Intermediates, Specialty Add...
How the Company Makes Money
LANXESS primarily makes money by manufacturing and selling specialty chemical products to business customers, generating revenue when products are delivered under customer contracts or purchase orders. Its key revenue streams are (a) specialty add...
LANXESS Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 13, 2026
Earnings Call Sentiment Neutral
The call balanced cautious optimism with clear risk awareness. Management signaled a sequential recovery into Q2 supported by pricing actions, recovering volumes in March/April, maintained full‑year guidance and tight working capital management. At the same time, Q1 was weak, input cost inflation (energy and precursors) will hit the Q2 P&L, geopolitical risk (Middle East) and raw‑material volatility create meaningful downside risk, and some structural/contingent liabilities (e.g., Envalior put) remain opaque. Overall, the positives (pricing, Q2 momentum, maintained guidance, working capital discipline) are offset by substantive near‑term cost and geopolitical headwinds.Positive Updates
Q2 Sequential Improvement Guidance
Management expects a clear sequential improvement in Q2 versus Q1 and provided a quantitative corridor for Q2 EBITDA contribution of EUR 130 million to EUR 150 million, highlighting stronger volumes and/or pricing as drivers.
Negative Updates
Soft Q1 Start and Lower Early-Quarter Volumes
Q1 began softly with notably lower volumes in January and February; management characterized Q1 as a weak start to the year driven by seasonality and market softness.
Read all updates
Q1-2026 Updates
Positive
Negative
Q2 Sequential Improvement Guidance
Management expects a clear sequential improvement in Q2 versus Q1 and provided a quantitative corridor for Q2 EBITDA contribution of EUR 130 million to EUR 150 million, highlighting stronger volumes and/or pricing as drivers.
Read all positive updates
Company Guidance
LANXESS kept its full‑year guidance unchanged and gave a quantitative corridor for Q2 of EUR 130–150 million (a strong sequential improvement versus Q1), while noting normal Q1 seasonality with negative cash flow, net working capital down year‑on‑year but expected to rise gradually in Q2, and net debt typically increasing EUR 100–200 million at the start of the year (but held at a comparable level through tight cash management). Management said April volumes were slightly above March with good visibility into May and softer indications for June, and pricing announced in March should phase in (first steps in April, ~two‑thirds in May and full effect by June). They warned input‑cost inflation seen in March will flow into Q2, bromine spot prices had peaked around EUR 60–70k and reverted to ~EUR 38–40k (still ~100% higher versus 1–2 years ago), and reiterated that if Q2 momentum continues they could move toward the upper end of the full‑year range but further Middle East escalation could push results toward the lower end.LANXESS Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
52
Neutral
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.45B | 5.67B | 6.37B | 6.71B | 8.09B | 7.56B |
| Gross Profit | 1.07B | 1.13B | 1.30B | 1.27B | 1.94B | 1.84B |
| EBITDA | 617.00M | 497.00M | 543.00M | -143.00M | 865.00M | 673.00M |
| Net Income | -661.00M | -577.00M | -177.00M | 443.00M | 185.00M | 267.00M |
Balance Sheet | ||||||
| Total Assets | 7.75B | 8.09B | 9.71B | 9.66B | 11.29B | 10.52B |
| Cash, Cash Equivalents and Short-Term Investments | 415.00M | 497.00M | 615.00M | 496.00M | 403.00M | 1.23B |
| Total Debt | 2.51B | 2.53B | 3.06B | 3.06B | 4.23B | 3.48B |
| Total Liabilities | 4.25B | 4.59B | 5.12B | 5.16B | 6.86B | 6.76B |
| Stockholders Equity | 3.49B | 3.50B | 4.59B | 4.50B | 4.42B | 3.76B |
Cash Flow | ||||||
| Free Cash Flow | 34.00M | -56.00M | 188.00M | 512.00M | -248.00M | -72.00M |
| Operating Cash Flow | 349.00M | 263.00M | 508.00M | 838.00M | 159.00M | 407.00M |
| Investing Cash Flow | 327.00M | 389.00M | -263.00M | 423.00M | -1.05B | -432.00M |
| Financing Cash Flow | -562.00M | -518.00M | -97.00M | -1.47B | 613.00M | 389.00M |
LANXESS Technical Analysis
Positive
17.88
Price Trends
17.31
Positive
17.39
Positive
19.96
Negative
Market Momentum
0.51
Negative
55.32
Neutral
29.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:LXS, the sentiment is Positive. The current price of 17.88 is above the 20-day moving average (MA) of 16.79, above the 50-day MA of 17.31, and below the 200-day MA of 19.96, indicating a neutral trend. The MACD of 0.51 indicates Negative momentum. The RSI at 55.32 is Neutral, neither overbought nor oversold. The STOCH value of 29.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:LXS.
LANXESS Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | €4.41B | 13.32 | 16.38% | 3.91% | 0.03% | 5.54% | |
64 Neutral | €8.30B | 15.61 | 1.89% | 8.92% | -9.37% | -47.49% | |
63 Neutral | €8.87B | 21.10 | 5.27% | 4.30% | -9.48% | -56.88% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
53 Neutral | €4.93B | 100.12 | -20.12% | 3.75% | ― | ― | |
49 Neutral | €1.60B | -2.86 | -17.77% | 0.59% | -14.31% | -386.04% | |
45 Neutral | €12.42B | -7.53 | -10.04% | ― | -8.72% | -140.66% |
* Basic Materials Sector Average
DE:LXS
LANXESS
18.55
-8.55
-31.54%
DE:BNR
Brenntag AG
61.40
3.53
6.09%
DE:1COV
Covestro
59.80
-0.62
-1.03%
DE:EVK
Evonik
17.81
-1.23
-6.45%
DE:FPE
Fuchs Petrolub
30.45
-2.70
-8.14%
DE:WCH
Wacker Chemie AG
99.20
35.05
54.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.